Dr. Ganesan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
550 First Ave
New York, NY 10016
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1996 - 1999- Brigham and Women's HospitalResidency, Internal Medicine, 1993 - 1996
Yale School of MedicineClass of 1993
Certifications & Licensure
NY State Medical License 2025 - 2026
NJ State Medical License 2005 - 2025
MA State Medical License 1996 - 2005
American Board of Internal Medicine Medical Oncology
Clinical Trials
- Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer Start of enrollment: 2024 Nov 15
Roles: Contact
Publications & Presentations
PubMed
- Occult collision tumor of the gastroesophageal junction comprising adenocarcinomas with distinct molecular profiles.Maryjka B Blaszczyk, Sarag A Boukhar, Zhongren Zhou, Lyudmyla Berim, Shridar Ganesan
Cancer Genetics. 2025-04-01 - Immune Checkpoint Blockade Delays Cancer Development and Extends Survival in DNA Polymerase Mutator Syndromes.Akshada Sawant, Fuqian Shi, Eduardo Cararo Lopes, Zhixian Hu, Somer Abdelfattah
Cancer Research. 2025-03-14 - Differences in COVID-19-Related Hospitalization, Treatment, Complications, and Death by Race and Ethnicity and Area-Level Measures Among Individuals with Cancer in the...Adiba Ashrafi, Yong Lin, Angela J Fong, Jessica Y Islam, Tiffany C Turner Anderson
Cancers. 2025-03-02
Journal Articles
- RET Rearrangements Are Actionable Alterations in Breast CancerShridar Ganesan, Siraj M Ali, Kim M Hirshfield, Nature
- PALB2 Connects BRCA1 and BRCA2 in the G2/M Checkpoint ResponseShridar Ganesan, MD, Nature
- Endogenous Retrovirus Expression Is Associated with Response to Immune Checkpoint Blockade in Clear Cell Renal Cell CarcinomaBenjamin G. Vincent, Jonathan S. Serody, Gregory Riedlinger, Shridar Ganesan, The Journal of Clinical Investigation
- Join now to see all
Press Mentions
Why NYU Langone Is Betting on Molecular OncologyJanuary 15th, 2025- NYU Langone Launches Molecular Oncology Program, Names LeaderOctober 11th, 2024
- NYU Langone Perlmutter Cancer Center Appoints Renowned Physician–Scientist to Build & Lead Groundbreaking Molecular Oncology ProgramOctober 10th, 2024
- Join now to see all
Grant Support
- Evolution and clinical impact of clonal hematopoiesis of indeterminate potential in breast tumor microenvironmentRUTGERS BIOMEDICAL AND HEALTH SCIENCES2019–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
